Abstract
The treatment of multiple acyl-CoA-dehydrogenase deficiency (MADD) includes a low-fat, low-protein, high-carbohydrate diet, avoiding long fasting periods. However, there is no useful biochemical marker to determine the response to different diets or fasting periods. The aims of this study are to report a patient with MADD, diagnosed through a newborn screening program using tandem mass spectrometry, to assess her response to different feedings, and to evaluate the usefulness of acylcarnitines and FFA to monitor the response to dietary changes. The patient was diagnosed at 6 d. Family history revealed three dead siblings. Five tests were performed, one with breast milk and the subsequent four after giving the patient a bottle of a low-fat, low-protein formula (F), F with glucose polymers (GP), F+GP plus uncooked corn starch (CS), or F+GP+CS preceded by amylase. The results showed that acylcarnitines, FFA, and total nonesterified fatty acids levels were greatly improved at 2 and 4 h on F+GP compared with breast milk. At 6 mo of age, the test with F+CS was repeated to assess the response to a longer fast. The results were similar at 2 and 4 h, but showed a marked increase of acylcarnitines, FFA, and total nonesterified fatty acids at 6 h. The increase of these metabolites could not be avoided by the use of F+GP+CS, but was prevented when amylase was used simultaneously. The patient is currently 3.9 y old and has normal growth and development. We conclude that diagnosis of MADD through a newborn screening program using tandem mass spectrometry is suitable; acylcarnitines and FFA are useful to monitor the response to treatment; and exogenous amylase allows the use of CS in small children with MADD. This therapeutic approach may be an alternative to the use of continuous overnight feedings used for young children with severe fatty acid oxidation defects. Early diagnosis and treatment may change the natural history of MADD.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- MADD:
-
multiple acyl-CoA-dehydrogenase deficiency
- AC:
-
acylcarnitines
- MS-MS:
-
tandem mass spectrometry
- BM:
-
breast milk
- F:
-
infant formula
- GP:
-
glucose polymers
- CS:
-
uncooked cornstarch
- NEFA:
-
total nonesterified fatty acids
- A:
-
amylase
- MCAD:
-
medium-chain acyl-CoA dehydrogenase
References
Frerman FE, Goodman SI 1995 Nuclear encoded defects of the mitochondrial respiratory chain, including glutaric acidemia type II. In: Scriver C. Beaudet L, Sly W, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, 1611–1631.
Nyhan WL, Ozand PT 1998 Multiple acyl-CoA-dehydrogenase deficiency/glutaric aciduria type II/ethylmalonic-adipic aciduria. In: Nyhan WL, Ozand PT (eds) Atlas of metabolic diseases. Chapman & Hall Medical, London, 245–252.
Rhead WJ, Wolff JA, Lipson M, Falace P, Desai N, Fritchman K, Moon A, Sweetman L 1987 Clinical and biochemical variation and family studies in the multiple acyl-CoA dehydrogenation disorders. Pediatr Res 21: 371–376
Turnbull DM, Barlett K, Eyre JA, Gardner-Medwin D, Johnson MA, Fisher J, Watmough NJ 1988 Lipid storage myopathy due to glutaric aciduria type II: treatment of a potentially fatal myopathy. Dev Med Child Neurol 30: 667–672
Mongini T, Doriguzi C, Palmucci L, DeFrancesco A, Bet L, Manfredi L, Ponzetto C, Bresolin N 1992 Lipid storage myopathy in multiple acyl-CoA dehydrogenase deficiency: an adult case. Eur Neurol 32: 170–176
Rinaldo P 1994 Laboratory diagnosis of inborn errors of metabolism. In: Suchy FJ (ed) Liver disease in children. Mosby, St. Louis, 295–308.
Rashed MS, Bucknall M, Little D, Awad A, Jacob M, Alamoudi M, Alwattar M, Ozand P 1997 Screening blood spots for inborn errors of metabolism by electrospray tandem mass spectrometry with a microplate batch process and a computer algorithm for automated flagging of abnormal profiles. Clin Chem 43: 1129–1141
Vreken P, Van Lint AEM, Bootsma AH, Overmars H, Wanders RJA, Van Gennip AH 1999 Quantitative plasma acylcarnitines analysis using electrospray tandem mass spectrometry for the diagnosis of organic acidemias and fatty acid oxidation defects. J Inher Metab Dis 22: 302–306
Naylor EW, Chase DH 1999 Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. J Child Neurol 14( suppl): S4–S8
Green A, Marshall TG, Gray RGF, Pollit RJ 1985 Riboflavin-responsive ethylmalonic-adipic aciduria. J Inher Metab Dis 8: 67–70
Brivet M, Tardieu M, Khellaf A, Boutron A, Rocchiccioli F, Haengeli CA, Lemonnier A 1991 Riboflavin responsive ethylmalonic-adipic aciduria in a 9-month-old boy with liver cirrhosis, myopathy and encephalopathy. J Inher Metab Dis 14: 333–337
Mooy PD, Przyrembel H, Giesberts MAH, Scarbohydrateslte HR, Blom W, van Gelderen HH 1984 Glutaric aciduria type II: treatment with riboflavine, carnitine and insulin. Eur J Pediatr 143: 92–95
Treem WR 1994 Inborn defects in mitochondrial fatty acid oxidation. In: Suchy FJ (ed) Liver disease in children. Mosby, St. Louis, 852–887.
Millington DS, Terada N, Chace DH, Chen YT, Ding JH, Kodo N, Roe CR 1992 The role of tandem mass spectrometry in the diagnosis of fatty acid oxidation disorders. In: Coates P, Tanaka K. (eds) New developments in fatty acid oxidation. Wiley-Liss, New York, 339–354.
Millington DS, Chace DH, Hillman SL, Kodo N, Terada N 1994 Diagnosis of metabolic disease. In: Matsuo T, Caprioli RM, Gross ML, Seyana Y (eds) Biological mass spectrometry: present and future. John Wiley & Sons, New York, 559–579.
Brivet M, Slama A, Saudubray JM, Legrand A, Lemonnier A 1995 Rapid diagnosis of long chain and medium chain fatty acid oxidation disorders using lymphocytes. Ann Clin Biochem 32: 154–159
Saudubray JM, Coude F, Damaugre F, Johnson C, Gibson K, Nyhan W 1982 Oxidation of fatty acid in cultured fibroblasts: a model system for the detection and study of defects in oxidation. Pediatr Res 16: 877–881
Costa CG, Dorland L, Holwerda U, Tavares de Almeida I, Poll-The WT, Jacobs C, Duran M 1998 Simultaneous analysis of plasma free fatty acids and their 3-hydroxy analogs in fatty acid B-oxidation disorders. Clin Chem 44: 463–471
Ducombe W 1963 The colorimetric microdetermination of long chain fatty acids. Biochem J 88: 7–10
Buttery JE, Chamberlain BR, Pannall PR 1984 Colorimetric measurement of abnormal level of 3-hidroxibutirate in plasma. Clin Chem Acta 139: 167–171
Slocum RH, Cummings JG 1991 Amino acid analysis of physiological samples. In: Hommes FA (ed) Techniques in diagnostic human genetics. Wiley-Liss, New York, 87–126.
Hoppel CL 1991 Determination of carnitine. In: Hommes FA (ed) Techniques in diagnostic human genetics. Wiley-Liss, New York, 309–326.
Abdenur JE, Chamoles NA, Specola N, Schenone AB, Jorge L, Guinle A, Bernard CI, Levandowskiy V, Lavorgna S 1999 MCAD deficiency: acylcarnitines by tandem mass spectrometry are useful to monitor dietary treatment. Adv Exp Med Biol 466: 353–363
Costa CG, Dorland L, Tavares de Almeida I, Jakobs C, Duran M, Poll-The B 1998 The effect of fasting, long-chain triglyceride load and carnitine load on plasma long-chain acylcarnitine levels in mitochondrial very long-chain acyl-CoA dehydrogenase deficiency. J Inher Metab Dis 21: 391–399
Abdenur JE, Chamoles NA, García Alvarez M, Artero M, Schenone AB, Levanodwskiy V, Lavorgna S 1999 Deficiencia de 3-hidroxi-acil-CoA-dehidrogenasa de cadena larga: utilidad de las acilcarnitinas en el diagnóstico y tratamiento. II Congreso Latinoamericano de Errores Innatos del Metabolismo y Pesquisa Neonatal. Santiago, Chile, October 24–27, abstract book, 110
Chen YT 1995 Glycogen storage diseases. In: Scriver C, Beaudet L, Sly W, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, 935–965.
Fernandes J, Chen YT 1995 Glycogen storage diseases. In: Fernandes J, Saudubray G, Van den Berghe G (eds) Inborn metabolic diseases. Springer-Verlag, Berlin, 71–85.
Schiffrin A, Polychronakos C, Abu-Srair H 1986 Glycogen storage disease type 1. Letter to the editor. N Engl J Med 315: 520–521
Trauner DA, Adams H 1981 Intracranial pressure elevations during octanoate infusion in rabbits: an experimental model of Reye's syndrome. Pediatr Res 15: 1097–1099
Abdenur JE, Chamoles NA, Guinle A, Schenone AB, Fuertes A 1998 Diagnosis of isovaleric acidemia by tandem mass spectrometry: false positive result due to pivaloylcarnitine in a newborn screening programme. J Inher Metab Dis 21: 624–630
Roe CR, Millington DS, Maltby DA, Kinnebrew P 1986 Recognition of medium-chain acyl-CoA dehydrogenase deficiency in asymptomatic siblings of children dying of sudden infant death or Reye-like syndromes. J Pediatr 108: 1–13
Acknowledgements
The authors thank Dr. S. I. Goodman for the revision of the manuscript, Dr. Caubet, Laboratorios Casasco, Argentina, who provided carnitine for the treatment of this patient, and the staff of the Department of Pediatric Endocrinology at the Hospital de Niños Pedro de Elizalde, who followed the patient during intercurrent illnesses.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abdenur, J., Chamoles, N., Schenone, A. et al. Multiple Acyl-CoA-Dehydrogenase Deficiency (MADD): Use of Acylcarnitines and Fatty Acids to Monitor the Response to Dietary Treatment. Pediatr Res 50, 61–66 (2001). https://doi.org/10.1203/00006450-200107000-00013
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/00006450-200107000-00013
